GlassScriptPhysician profile
Blake Thomas Blancher
NPI 1871099408
$3,627.84
in general payments reported to CMS, 2019-2025
46 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $183 · 2024: $699 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,338 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,337.91 |
| Education | $289.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $394.42 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $242.80 | 2024-2025 | Keytruda, Lynparza |
| Celgene Corporation | $212.21 | 2024-2025 | Reblozyl, Opdivo |
| Novartis Pharmaceuticals Corporation | $184.70 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $162.67 | 2025 | Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $160.58 | 2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $147.29 | 2023-2025 | Xtandi, Vyloy |
| Pfizer INC. | $144.23 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.56 | 2023-2025 | Ninlaro, Alunbrig |
| Stemline Therapeutics INC. | $118.92 | 2024-2025 | Orserdu |
| Genzyme Corporation | $113.21 | 2024-2025 | |
| Gilead Sciences, INC. | $107.40 | 2024-2025 | Trodelvy |
| Daiichi Sankyo INC. | $92.11 | 2024-2025 | Enhertu, Datroway |
| Abbvie INC. | $88.72 | 2025 | |
| Eisai INC. | $81.28 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $81.01 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $80.84 | 2024-2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $76.98 | 2024-2025 | Venclexta, Itovebi |
| Beigene USA, INC. | $69.91 | 2024-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $64.43 | 2025 | Libtayo |
| Array Biopharma INC | $62.59 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Servier Pharmaceuticals LLC | $62.16 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $56.68 | 2025 | |
| Adaptive Biotechnologies Corporation | $51.93 | 2024-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.70 | 2024-2025 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $48.89 | 2024-2025 | |
| Glaxosmithkline, LLC. | $42.34 | 2025 | Ojjaara, Jemperli, Zejula |
| Novocure INC. | $40.06 | 2025 | Optune Lua (Novottf-200t) |
| Immunocore Limited | $38.24 | 2025 | Kimmtrak |
| Kite Pharma, INC. | $35.54 | 2025 | Yescarta |
| Ferring Pharmaceuticals INC. | $35.50 | 2025 | Adstiladrin |
| Tempus Ai, INC | $34.91 | 2025 | Xt Cdx |
| Caris Mpi, INC. | $34.81 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $33.77 | 2025 | |
| Pharmaessentia USA Corporation | $32.81 | 2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $27.43 | 2025 | Onivyde, Somatuline Depot |
| Rigel Pharmaceuticals, INC. | $27.35 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $26.30 | 2024 | Epkinly |
| Spectrum Pharmaceuticals INC. | $20.83 | 2025 | Rolvedon |
| Dendreon Pharmaceuticals LLC | $20.56 | 2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $20.02 | 2025 | |
| Tactile Systems Technology INC | $19.06 | 2024 | Flexitouch Plus, Entre Plus |
| Deciphera Pharmaceuticals INC. | $17.71 | 2025 | Qinlock |
| Puma Biotechnology, INC. | $15.51 | 2025 | |
| Sumitomo Pharma America, INC. | $15.41 | 2024 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $14.46 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Blancher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.